MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Pfizer

Atvērts

SektorsVeselības aprūpe

27.62 2.68

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

26.63

Max

27.56

Galvenie mērījumi

By Trading Economics

Ienākumi

-45M

2.9B

Pārdošana

938M

15B

P/E

Sektora vidējais

12.553

35.739

EPS

0.51

Dividenžu ienesīgums

7.15

Peļņas marža

19.982

Darbinieki

81,000

EBITDA

266M

5.3B

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+4.85% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

7.15%

3.08%

Nākamie ieņēmumi

2025. g. 4. nov.

Nākamais dividenžu datums

2025. g. 1. dec.

Nākamais Ex dividenžu datums

2025. g. 7. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.8B

136B

Iepriekšējā atvēršanas cena

24.94

Iepriekšējā slēgšanas cena

27.62

Ziņu noskaņojums

By Acuity

46%

54%

140 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Pfizer Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 1. okt. 08:54 UTC

Galvenie tirgus virzītāji

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

2025. g. 30. sept. 15:07 UTC

Galvenie tirgus virzītāji

Pfizer Shares Rise After WSJ Reports Company Will Lower Drug Costs

2025. g. 22. sept. 14:54 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- 2nd Update

2025. g. 22. sept. 11:51 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

2025. g. 22. sept. 11:09 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion

2025. g. 22. sept. 10:13 UTC

Galvenie tirgus virzītāji
Iegādes, apvienošanās, pārņemšana

Metsera Shares Leap Premarket on Report of Takeover by Pfizer

2025. g. 22. sept. 07:42 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer Nears $7.3 Billion Metsera Deal, FT Says, Citing Sources

2025. g. 5. aug. 11:34 UTC

Peļņas

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

2025. g. 22. sept. 15:17 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer Jumps Back into the Weight-Loss Race With $4.9B Acquisition -- Barrons.com

2025. g. 22. sept. 13:43 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

2025. g. 22. sept. 11:26 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Fox, Coinbase, Metsera, Pfizer, Kenvue, Anywhere Real Estate, Premier, and More -- Barrons.com

2025. g. 22. sept. 11:26 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- WSJ

2025. g. 22. sept. 10:48 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer: Metsera Deal Adds Four Clinical-Stage Incretin, Amylin Programs to Pipeline >PFE MTSR

2025. g. 22. sept. 10:47 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer: Metsera Deal Includes Contingent Value Rights Worth Up to Additional $22.50/Share >PFE MTSR

2025. g. 22. sept. 10:46 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer: Metsera Deal Has Initial Enterprise Value of $4.9 Billion >PFE MTSR

2025. g. 22. sept. 10:45 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer to Pay Initial $47.50/Share for Metsera >PFE MTSR

2025. g. 22. sept. 10:45 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer to Acquire Metsera and Its Next-Generation Obesity Portfolio >PFE MTSR

2025. g. 22. sept. 09:12 UTC

Karstas akcijas

Stocks to Watch Monday: Nippon Steel, Porsche, Infosys, Metsera -- WSJ

2025. g. 5. aug. 20:44 UTC

Peļņas

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

2025. g. 5. aug. 18:20 UTC

Peļņas

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

2025. g. 5. aug. 18:17 UTC

Peļņas

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

2025. g. 5. aug. 16:04 UTC

Tirgus saruna

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

2025. g. 5. aug. 15:25 UTC

Peļņas

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

2025. g. 5. aug. 13:56 UTC

Peļņas

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

2025. g. 5. aug. 11:43 UTC

Peļņas

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

2025. g. 5. aug. 11:27 UTC

Peļņas

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

2025. g. 5. aug. 10:57 UTC

Peļņas

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

2025. g. 5. aug. 10:55 UTC

Peļņas

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

2025. g. 5. aug. 10:53 UTC

Peļņas

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

2025. g. 5. aug. 10:51 UTC

Peļņas

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

Salīdzinājums

Cenas izmaiņa

Pfizer Prognoze

Cenas mērķis

By TipRanks

4.85% augšup

Prognoze 12 mēnešiem

Vidējais 28.53 USD  4.85%

Augstākais 34 USD

Zemākais 24 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pfizer  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

17 ratings

4

Pirkt

12

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

22.855 / 23.85Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

140 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat